Xiaowei Xu

Oct 11, 2024 | digitalcommons.library.tmc.edu | Payal Shah |Alexander Huang |Xiaowei Xu |Robert Orlowski

PURPOSE: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET. EXPERIMENTAL DESIGN: Metastatic melanoma or mTNBC subjects had at least 30% tumor expression of cMET, measurable disease and progression on prior therapy.

Apr 11, 2024 | nber.org | David Blanchflower |Alex Bryson |Xiaowei Xu

We thank the United Nations for financial support and Sian Beilock, Andrew Campbell, Pedro Conceiaco, Carol Graham, Josefin Pasanen, Jon Skinner and Bruce Sacerdote for helpful comments and suggestions and Gabriel Gottesman for research assistance. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. Related

Nov 17, 2023 | science.org | Xiaowei Xu |Giuseppe Curigliano |Erika Gebel Berg

Register NOWRemaining time: 10 DAYS | 10 HRS | 32 MINS Xiaowei Xu, M.D., Ph.D.Speaker Giuseppe Curigliano, M.D., Ph.D.Speaker Erika Gebel Berg, Ph.D.Moderator By some estimates, 96% of experimental drugs fail to make it to market. Not only does this mean that people are left without life-saving medications, but scientists are wasting an enormous amount of time and resources on dead-end projects. New methods are needed to make the drug development process more efficient. Cancer immunotherapy...